Many people living with COPD continue to experience significant symptoms and exacerbations despite optimised pharmacological and non-pharmacological management. For these patients, emerging biologic therapies may offer a new approach to improving symptoms, reducing exacerbations and supporting quality of life.
Understanding when biologics may be appropriate starts with ensuring COPD has been accurately diagnosed and that standard management has been optimised. But how do you identify patients who may benefit from biologic therapy, and when should they be referred for specialist assessment?
Hear from our expert panel about the current role of biologics in COPD, the evidence behind these therapies, who may be eligible for treatment, and practical considerations for identifying and referring appropriate patients.
Ask the panel your questions at registration, or live during the Q&A session.
Learning outcomes
- Describe the key components of optimised COPD management, including pharmacological and non-pharmacological management, inhaler technique and management of comorbidities.
- Outline the role of biologic therapies in COPD, including their rationale, mechanisms of action and the evidence supporting their use.
- Identify patients who may be eligible for biologic therapy and describe appropriate referral pathways and considerations for specialist assessment.
This virtual learning event is accredited with RACGP for one hour of Educational Activity (EA).
